Aegis Begins Coverage on Cingulate (NASDAQ:CING)

Aegis started coverage on shares of Cingulate (NASDAQ:CING) in a research note published on Tuesday, The Fly reports. The firm issued a buy rating and a $9.00 price target on the stock.

Shares of CING stock opened at $2.60 on Tuesday. Cingulate has a twelve month low of $2.20 and a twelve month high of $5.15.

Cingulate Company Profile

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release(TM) drug delivery platform technology to build and advance a pipeline of pharmaceutical products. Cingulate Inc is based in KANSAS CITY, Kan.

Featured Story: What is the NASDAQ Stock Market?

The Fly logo

Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with's FREE daily email newsletter.